The neuropeptides VIP and PACAP inhibit IL-2 transcription by decreasing c-Jun and increasing JunB expression in T cells.
J Neuroimmunol
; 104(1): 68-78, 2000 Apr 03.
Article
em En
| MEDLINE
| ID: mdl-10683516
ABSTRACT
Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) act as macrophage and T-cell deactivators. Previously we established that VIP/PACAP limit T-cell activation directly, by inhibiting interleukin 2 (IL-2), and indirectly, by reducing the macrophage costimulatory functions. The nature of the IL-2 transcriptional factors affected by VIP/PACAP has not been elucidated. Here we investigate the effect of VIP on the AP-l complexes bound to several regulatory sites. VIP/PACAP downregulate c-Jun, and upregulate JunB mRNA and protein. The reduction in c-Jun correlates with the inhibition of the c-Jun N-terminal kinase (JNK). The effects of VIP/PACAP on c-Jun and JunB expression lead to changes in the composition of the AP-l complexes, from c-Jun/Fos to JunB/Fos dimers, with a subsequent decrease in DNA binding and loss of transactivating activity.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Transcrição Gênica
/
Neuropeptídeos
/
Peptídeo Intestinal Vasoativo
/
Linfócitos T
/
Interleucina-2
/
Proteínas Proto-Oncogênicas c-jun
Limite:
Animals
Idioma:
En
Revista:
J Neuroimmunol
Ano de publicação:
2000
Tipo de documento:
Article
País de afiliação:
Estados Unidos